Insulin icodec/semaglutide is an experimental fixed-dose combination of insulin icodec and semaglutide in development for type 2 diabetes by Novo Nordisk. The combination contains insulin icodec, a basal insulin analog; and semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.